XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 2 - Significant Transactions - Allocation of Preliminary Price (Details) - USD ($)
$ in Thousands
Oct. 20, 2021
Sep. 30, 2022
Mar. 31, 2022
Goodwill, Ending Balance   $ 278,006 $ 291,166
Agena [Member]      
Cash and cash equivalents $ 7,544    
Accounts receivable [1] 11,100    
Other current assets [2] 25,480    
Total current assets 44,124    
Property, plant and equipment/noncurrent assets 15,832    
Deferred tax asset 811    
Goodwill, Ending Balance 136,260 [3]   $ 136,260
Total Assets acquired 361,927    
Accounts payable 2,174    
Unearned revenues 2,713    
Other current liabilities 12,217    
Total current liabilities 17,104    
Deferred tax liability 28,223    
Other noncurrent liabilities 8,263    
Total liabilities assumed 53,590    
Total purchase price, net of cash acquired $ 300,793    
Agena [Member] | Customer Relationships [Member]      
Intangible assets, life (Year) 12 years    
Intangible assets [4] $ 103,800    
Intangible assets, life (Year) 12 years    
Agena [Member] | Intellectual Property [Member]      
Intangible assets, life (Year) 8 years    
Intangible assets [4] $ 45,400    
Intangible assets, life (Year) 8 years    
Agena [Member] | Trade Names [Member]      
Intangible assets, life (Year) 12 years    
Intangible assets [4] $ 15,700    
Intangible assets, life (Year) 12 years    
[1] Trade receivables, net, which is expected to be collected.
[2] Includes $7,462 of inventory step-up, which was amortized entirely within fiscal year 2022. Our evaluation of the valuation of inventory was complete as of March 31, 2022.
[3] Acquired goodwill of $140,022, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from the value of expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.
[4] Customer relationships, intellectual property, and tradenames are currently expected to be amortized on a straight line basis over a weighted average 8.3 year period. The identified intangible assets will be amortized on a straight line basis over their useful lives, which approximates the pattern over which the assets' economic benefits are expected to be consumed over time. Amortization expense for customer relationships and tradenames will be amortized to general and administrative expenses; amortization expense for intellectual property will be recorded to cost of revenues. During the period from October 20, 2021 until March 31, 2022, $6,728 of amortization expense was recorded to general and administrative costs and $2,538 of amortization expense was recorded to cost of revenues in the Clinical Genomics Division, including the cumulative effect catch up. Our valuation of intangible assets is considered to be complete as of March 31, 2022. Going forward, we expect to record amortization expense of $3,668 and $1,419 to general and administrative costs and costs of revenues, respectively, each quarter.